Collection on molecular imaging in neurodegeneration.

Molecular imaging, including positron emission tomography (PET) and single photon emission computed tomography (SPECT), along with functional and structural imaging by magnetic resonance imaging, provides precision approaches to facilitate the diagnosis of neurogenerative diseases [[3]-[5]]. Amyloid and tau PET imaging has demonstrated the clinical utility, providing tools to evaluate the disease stages, improve the diagnostic accuracy, and monitor the efficacy of interventions. The prevalence and incidence of neurogenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are rapidly increasing with the aging society [[1]]. [Extracted from the article]